Becton, Dickinson and Company (BDX) FY2025 YTD Q3 P&L / Income Statement

Becton, Dickinson and Company (BDX) FY2025 YTD Q3 P&L / Income Statement

Income statement for 2024-10-01 through 2025-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

15,949,000,000 US dollars

Cost of products sold

8,823,000,000 US dollars

Gross profit (calculated)

7,126,000,000 US dollars

Operating expenses (calculated)

5,244,000,000 US dollars

Operating Income

1,882,000,000 US dollars

Other income (expense), net (calculated)

negative 511,000,000 US dollars

Income Before Income Taxes

1,371,000,000 US dollars

Income tax provision

186,000,000 US dollars

Net Income

1,185,000,000 US dollars

Medical

8,302,000,000 US dollars

Life Sciences

3,798,000,000 US dollars

Interventional

3,849,000,000 US dollars

Integration, restructuring and transaction expense

279,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Research and development expense

943,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Selling and administrative expense

3,912,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Other operating expense, net

111,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.